Jason R Crawford1, Hua Yang2, Peter Kunz2, D Scott Wilbur3, Paul Schaffer2, Thomas J Ruth4. 1. TRIUMF, 4004 Wesbrook Mall, Vancouver, British Columbia V6T 2A3, Canada; Department of Physics and Astronomy, University of Victoria, 3800 Finnerty Road, Victoria, British Columbia V8P 5C2, Canada. Electronic address: jcrawford@triumf.ca. 2. TRIUMF, 4004 Wesbrook Mall, Vancouver, British Columbia V6T 2A3, Canada. 3. Department of Radiation Oncology, University of Washington (Box 355016), 616 N.E. Northlake Place, Seattle, WA 98105, USA. 4. TRIUMF, 4004 Wesbrook Mall, Vancouver, British Columbia V6T 2A3, Canada; Department of Physics and Astronomy, University of Victoria, 3800 Finnerty Road, Victoria, British Columbia V8P 5C2, Canada.
Abstract
INTRODUCTION: The availability of 211At for targeted alpha therapy research can be increased by the 211Rn/211At generator system, whereby 211At is produced by 211Rn electron capture decay. This study demonstrated the feasibility of using generator-produced 211At to label monoclonal antibody (BC8, anti-human CD45) for preclinical use, following isolation from the 207Po contamination also produced by these generators (by 211Rn α-decay). METHODS: 211Rn was produced by 211Fr electron capture decay following mass separated ion beam implantation and chemically isolated in liquid alkane hydrocarbon (dodecane). 211At produced by the resulting 211Rn source was extracted in strong base (2N NaOH) and purified by granular Te columns. BC8-B10 (antibody conjugated with closo-decaborate(2-)) was labeled with generator-produced 211At and purified by PD-10 columns. RESULTS: Aqueous solutions extracted from the generator were found to contain 211At and 207Po, isolated from 211Rn. High radionuclidic purity was obtained for 211At eluted from Te columns, from which BC8-B10 monoclonal antibody was successfully labeled. If not removed, 207Po was found to significantly contaminate the final 211At-BC8-B10 product. High yield efficiencies (decay-corrected, n=3) were achieved for 211At extraction from the generator (86%±7%), Te column purification (70%±10%), and antibody labeling (76%±2%). CONCLUSIONS: The experimental 211Rn/211At generator was shown to be well-suited for preclinical 211At-based research. ADVANCES IN KNOWLEDGE: We believe that these experiments have furthered the knowledge-base for expanding accessibility to 211At using the 211Rn/211At generator system. IMPLICATIONS FOR PATIENT CARE: As established by this work, the 211Rn/211At generator has the capability of facilitating preclinical evaluations of 211At-based therapies.
INTRODUCTION: The availability of 211At for targeted alpha therapy research can be increased by the 211Rn/211At generator system, whereby 211At is produced by 211Rn electron capture decay. This study demonstrated the feasibility of using generator-produced 211At to label monoclonal antibody (BC8, anti-human CD45) for preclinical use, following isolation from the 207Po contamination also produced by these generators (by 211Rn α-decay). METHODS: 211Rn was produced by 211Fr electron capture decay following mass separated ion beam implantation and chemically isolated in liquid alkane hydrocarbon (dodecane). 211At produced by the resulting 211Rn source was extracted in strong base (2N NaOH) and purified by granular Te columns. BC8-B10 (antibody conjugated with closo-decaborate(2-)) was labeled with generator-produced 211At and purified by PD-10 columns. RESULTS: Aqueous solutions extracted from the generator were found to contain 211At and 207Po, isolated from 211Rn. High radionuclidic purity was obtained for 211At eluted from Te columns, from which BC8-B10 monoclonal antibody was successfully labeled. If not removed, 207Po was found to significantly contaminate the final 211At-BC8-B10 product. High yield efficiencies (decay-corrected, n=3) were achieved for 211At extraction from the generator (86%±7%), Te column purification (70%±10%), and antibody labeling (76%±2%). CONCLUSIONS: The experimental 211Rn/211At generator was shown to be well-suited for preclinical 211At-based research. ADVANCES IN KNOWLEDGE: We believe that these experiments have furthered the knowledge-base for expanding accessibility to 211At using the 211Rn/211At generator system. IMPLICATIONS FOR PATIENT CARE: As established by this work, the 211Rn/211At generator has the capability of facilitating preclinical evaluations of 211At-based therapies.
Authors: Diane E Milenic; Kwamena E Baidoo; Young-Seung Kim; Rachel Barkley; Martin W Brechbiel Journal: Dalton Trans Date: 2017-10-31 Impact factor: 4.390
Authors: Valery Radchenko; Alfred Morgenstern; Amir R Jalilian; Caterina F Ramogida; Cathy Cutler; Charlotte Duchemin; Cornelia Hoehr; Ferrid Haddad; Frank Bruchertseifer; Haavar Gausemel; Hua Yang; Joao Alberto Osso; Kohshin Washiyama; Kenneth Czerwinski; Kirsten Leufgen; Marek Pruszyński; Olga Valzdorf; Patrick Causey; Paul Schaffer; Randy Perron; Samsonov Maxim; D Scott Wilbur; Thierry Stora; Yawen Li Journal: J Nucl Med Date: 2021-07-22 Impact factor: 11.082
Authors: Yawen Li; Donald K Hamlin; Ming-Kuan Chyan; Taylor M Morscheck; Maryline G Ferrier; Roger Wong; D Scott Wilbur Journal: Sci Rep Date: 2019-11-18 Impact factor: 4.379
Authors: Caterina F Ramogida; Andrew K H Robertson; Una Jermilova; Chengcheng Zhang; Hua Yang; Peter Kunz; Jens Lassen; Ivica Bratanovic; Victoria Brown; Lily Southcott; Cristina Rodríguez-Rodríguez; Valery Radchenko; François Bénard; Chris Orvig; Paul Schaffer Journal: EJNMMI Radiopharm Chem Date: 2019-08-06